174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
Titel:
174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
Auteur:
Balmana, J. Fasching, P.A. Delaloge, S. Park, Y.H. Eisen, A. Bourgeois, H. Kemp, Z. Jankowski, T. Sohn, J. Aksoy, S. Timcheva, C.V. Park-Simon, T-W. Anton Torres, A. John, E. Baria, K. Walker, G. Gelmon, K.A.